Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Co-Diagnostics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SALT LAKE CITY , DEC. 18, 2025 /PRNEWSWIRE/ -- CO-DIAGNOSTICS, INC. (NASDAQ: CODX)("CO-DX" OR "THE COMPANY"), A MOLECULAR DIAGNOSTICS COMPANY WITH A UNIQUE, PATENTED PLATFORM FOR THE DEVELOPMENT OF MOLECULAR DIAGNOSTIC TESTS, TODAY ANNOUNCED THAT ITS JOINT VENTURE, COSARA DIAGNOSTICS PVT. LTD. ("COSARA"), HAS BEEN INVITED TO PARTICIPATE IN THE 2ND ADVANCED TB DIAGNOSTICS COURSE, A CAPACITY-BUILDING WORKSHOP FOR COUNTRIES IN THE SOUTH-EAST ASIAN REGION (SEAR).

CO-DIAGNOSTICS JOINT VENTURE, COSARA, INVITED TO PARTICIPATE IN 2ND ADVANCED TB DIAGNOSTICS COURSE IN CHENNAI, INDIA

SALT LAKE CITY , DEC. 17, 2025 /PRNEWSWIRE/ -- CO-DIAGNOSTICS, INC. (NASDAQ: CODX) ("CO-DX" OR "THE COMPANY"), A MOLECULAR DIAGNOSTICS COMPANY WITH A UNIQUE, PATENTED PLATFORM FOR THE DEVELOPMENT OF MOLECULAR DIAGNOSTIC TESTS, TODAY ANNOUNCED THAT IT HAS PERFORMED AN IN SILICO ANALYSIS OF THE CO-PRIMERS USED IN ITS LOGIX SMART ABC TEST* FOR THE DETECTION OF INFLUENZA A, INFLUENZA B AND COVID-19. THE ANALYSIS SHOWED A HIGH HOMOLOGY AGAINST 3,900 INFLUENZA SEQUENCES, CONFIRMING COMPARABLE REACTIVITY OF THE PRIMER SETS AGAINST THE INFLUENZA A H3N2 SUBCLADE K.

CO-DIAGNOSTICS PERFORMS ANALYSIS OF INFLUENZA CO-PRIMERS TO CONFIRM REACTIVITY AGAINST FLU A H3N2 MUTATION

SALT LAKE CITY , DEC. 9, 2025 /PRNEWSWIRE/ --CO-DIAGNOSTICS, INC. (NASDAQ: CODX) ("CO-DX" OR "THE COMPANY"), A MOLECULAR DIAGNOSTICS COMPANY WITH A UNIQUE, PATENTED PLATFORM FOR THE DEVELOPMENT OF MOLECULAR DIAGNOSTIC TESTS, TODAY ANNOUNCED THAT THE COMPANY IS DELIVERING A PRESENTATION AT THE POINT-OF-CARE TESTING 2025 EXHIBITION AND CONFERENCE IN BOSTON, MA. THE PRESENTATION, TITLED "EXPLORING THE PROMISE OF PORTABLE, CLOUD-CONNECTED PCR DIAGNOSTICS," WILL UNPACK CO-DX'S MOVE TO PORTABLE PCR DIAGNOSTICS TO ADDRESS EVOLVING POINT-OF-CARE NEEDS, INTRODUCE THE COMPANY'S UPCOMING CO-DX PCR PLATFORM* AND INTUITIVE SMARTPHONE INTERFACE, AND DISCUSS HOW CO-DX IS HARNESSING AI TO MINIMIZE USER ERROR AND IMPROVE OUTCOMES IN REAL-TIME POINT-OF-CARE TESTING.

CO-DIAGNOSTICS TO PRESENT ON CO-DX PCR PLATFORM AND AI INTEGRATION AT POINT-OF-CARE TESTING 2025

ONGOING PHASE II PRECLINICAL STUDY DATA FOR CO-DX PCR MTB AND HPV TESTS SUPPORT ADVANCEMENT TO CLINICAL PERFORMANCE TESTING SALT LAKE CITY , DEC. 9, 2025 /PRNEWSWIRE/ --CO-DIAGNOSTICS, INC. (NASDAQ: CODX)("CO-DX" OR "THE COMPANY"), A MOLECULAR DIAGNOSTICS COMPANY WITH A UNIQUE, PATENTED PLATFORM FOR THE DEVELOPMENT OF MOLECULAR DIAGNOSTIC TESTS, TODAY ANNOUNCED THAT COSARA DIAGNOSTICS PVT. LTD. ("COSARA"), THE JOINT VENTURE ("JV") BETWEEN AMBALAL SARABHAI ENTERPRISES LIMITED (ASE GROUP) AND CO-DX, WILL PARTICIPATE AND HOST A BOOTH AT VIROCON 2025, TAKING PLACE DECEMBER 8-10 AT THE CONRAD HOTEL IN PUNE, MAHARASHTRA, INDIA.

CO-DIAGNOSTICS JV, COSARA, TO PARTICIPATE AT VIROCON 2025 IN PUNE, INDIA

SALT LAKE CITY , NOV. 20, 2025 /PRNEWSWIRE/ -- CO-DIAGNOSTICS, INC. (NASDAQ: CODX) (THE "COMPANY" OR "CO-DX"), A MOLECULAR DIAGNOSTICS COMPANY WITH A UNIQUE, PATENTED PLATFORM FOR THE DEVELOPMENT OF MOLECULAR DIAGNOSTIC TESTS, TODAY ANNOUNCED THAT THE COMPANY'S EXECUTIVE VICE PRESIDENT OF BUSINESS DEVELOPMENT, JOSEPH FEATHERSTONE, ADDRESSED A SATELLITE SESSION OF THE INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE (THE UNION) 2025 WORLD CONFERENCE ON LUNG HEALTH EARLIER TODAY IN COPENHAGEN, DENMARK, IN A TALK PROVIDING INDUSTRY PERSPECTIVE ON ADOPTION AND IMPLEMENTATION OF A TUBERCULOSIS MOLECULAR DIAGNOSTIC TEST. FOR OVER 100 YEARS, THE UNION WORLD CONFERENCE ON LUNG HEALTH HAS COME TOGETHER TO PRESENT THE LATEST SCIENTIFIC RESEARCH IN ALL ASPECTS OF LUNG HEALTH.

CO-DIAGNOSTICS DELIVERS ADDRESS ABOUT TUBERCULOSIS TEST ADOPTION AND IMPLEMENTATION AT THE UNION WORLD CONFERENCE ON LUNG HEALTH

SALT LAKE CITY , NOV. 18, 2025 /PRNEWSWIRE/ -- CO-DIAGNOSTICS, INC. (NASDAQ: CODX) (THE "COMPANY" OR "CO-DX"), A MOLECULAR DIAGNOSTICS COMPANY WITH A UNIQUE, PATENTED PLATFORM FOR THE DEVELOPMENT OF MOLECULAR DIAGNOSTIC TESTS, TODAY ANNOUNCED THAT IT HAS BEGUN CLINICAL EVALUATIONS FOR ITS CO-DX PCR FLU A/B, COVID-19, RSV TEST KIT. THE CLINICAL PERFORMANCE TESTING IS EXPECTED TO SUPPORT A SUBMISSION TO THE UNITED STATES FOOD AND DRUG ADMINISTRATION ("FDA") FOR 510(K) CLEARANCE OF THE UPPER RESPIRATORY MULTIPLEX POINT-OF-CARE TEST, AND THE CO-DX PCR PRO* INSTRUMENT.

CO-DIAGNOSTICS INITIATES CLINICAL EVALUATIONS FOR UPPER RESPIRATORY MULTIPLEX POINT-OF-CARE TEST ON CO-DX PCR PLATFORM TO SUPPORT SUBMISSION TO THE U.S. FDA

SALT LAKE CITY , NOV. 13, 2025 /PRNEWSWIRE/ -- CO-DIAGNOSTICS, INC. (NASDAQ: CODX) ("CO-DIAGNOSTICS," "CO-DX," OR "THE COMPANY"), A MOLECULAR DIAGNOSTICS COMPANY WITH A UNIQUE, PATENTED PLATFORM FOR THE DEVELOPMENT OF MOLECULAR DIAGNOSTIC TESTS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025. THIRD QUARTER 2025 BUSINESS HIGHLIGHTS: PERFORMED IN-SILICO ANALYSIS OF THE PRIMER SETS USED IN ITS CO-PRIMERS-BASED PCR TESTS FOR THE DETECTION OF CHIKUNGUNYA VIRUS (CHIKV), SHOWING HIGH HOMOLOGY AGAINST OVER 1,200 CHIKV SEQUENCES AND CONFIRMING REACTIVITY OF CHIKV PRIMERS AGAINST KNOWN RECENT STRAINS OF THE VIRUS COMPANY CLOSED ON A REGISTERED DIRECT OFFERING (RDO) WITH GROSS PROCEEDS OF APPROXIMATELY $3.8 MILLION BEFORE DEDUCTING OFFERING EXPENSES BUSINESS HIGHLIGHTS SUBSEQUENT TO THIRD QUARTER 2025: SIGNED DEFINITIVE AGREEMENT WITH ARABIAN EAGLE MANUFACTURING TO RESEARCH, DEVELOP, MANUFACTURE, ASSEMBLE, DISTRIBUTE, AND COMMERCIALIZE CO-DX TECHNOLOGIES AND INTELLECTUAL PROPERTY IN KSA AND 18 MENA NATIONS THROUGH THE JV COMIRA DIAGNOSTICS, FULFILLING THE OBJECTIVE OF THE MOU SIGNED IN SEPTEMBER 2025.

CO-DIAGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

SALT LAKE CITY , NOV. 5, 2025 /PRNEWSWIRE/ -- CO-DIAGNOSTICS, INC. (NASDAQ: CODX) (THE "COMPANY" OR "CO-DX"), A MOLECULAR DIAGNOSTICS COMPANY WITH A PATENTED PLATFORM FOR DEVELOPING ADVANCED MOLECULAR DIAGNOSTIC TESTS, TODAY ANNOUNCED THAT IT HAS ENGAGED MAXIM GROUP LLC ("MAXIM") AS ITS EXCLUSIVE FINANCIAL ADVISOR TO ASSIST THE COMPANY IN IDENTIFYING POTENTIAL STRATEGIC ALTERNATIVES FOR THE COMPANY'S INDIAN JOINT VENTURE, COSARA DIAGNOSTICS PVT. LTD. ("COSARA"), INCLUDING A MERGER WITH A SPECIAL PURPOSE ACQUISITION COMPANY ("SPAC") OR SIMILAR ENTITY LISTED ON A U.S. NATIONAL SECURITIES EXCHANGE.

CO-DIAGNOSTICS ENGAGES MAXIM GROUP TO PURSUE SPAC TRANSACTION FOR ITS INDIAN JOINT VENTURE, COSARA DIAGNOSTICS PVT. LTD

COMPANY FORMS NEW AI BUSINESS UNIT, LED BY CHIEF TECHNOLOGY & AI OFFICER CHRISTOPHER THURSTON, TO UNIFY AND ADVANCE CO-DX'S EXISTING AND FUTURE AI INITIATIVES SALT LAKE CITY , NOV. 3, 2025 /PRNEWSWIRE/ -- CO-DIAGNOSTICS, INC.(NASDAQ: CODX) (THE "COMPANY" OR "CO-DX"), A MOLECULAR DIAGNOSTICS COMPANY WITH A UNIQUE, PATENTED PLATFORM FOR THE DEVELOPMENT OF MOLECULAR DIAGNOSTIC TESTS, TODAY ANNOUNCED THE FORMATION OF A NEWLY ORGANIZED, ARTIFICIAL INTELLIGENCE ("AI") BUSINESS UNIT, LED BY CHIEF TECHNOLOGY & AI OFFICER CHRISTOPHER THURSTON, TO INTEGRATE THE COMPANY'S EXISTING AND PLANNED AI APPLICATIONS INTO THE CO-DX PRIMER AI PLATFORM. CO-DX ANTICIPATES THAT ALLOCATING RESOURCES TO THE NEWLY FORMED AI BUSINESS UNIT WILL ENABLE THE COMPANY TO DEVELOP PROPRIETARY AI-POWERED DIAGNOSTICS MORE EFFICIENTLY AND REDUCE TIME-TO-MARKET FOR NEW TESTS.

CO-DIAGNOSTICS TO INTEGRATE AND IMPLEMENT PROPRIETARY ARTIFICIAL INTELLIGENCE TECHNOLOGY INTO CO-DX PRIMER AI PLATFORM

SALT LAKE CITY , OCT. 31, 2025 /PRNEWSWIRE/ --CO-DIAGNOSTICS, INC.(NASDAQ: CODX), A MOLECULAR DIAGNOSTICS COMPANY WITH A UNIQUE, PATENTED PLATFORM FOR THE DEVELOPMENT OF MOLECULAR DIAGNOSTIC TESTS, ANNOUNCED TODAY IT WILL RELEASE ITS THIRD QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, NOVEMBER 13, 2025, AFTER THE MARKET CLOSE. THE COMPANY WILL ALSO HOST A CONFERENCE CALL AND WEBCAST ON THE SAME DAY AT 4:30 P.M.

CO-DIAGNOSTICS, INC. ANNOUNCES THIRD QUARTER 2025 EARNINGS RELEASE DATE AND WEBCAST

SALT LAKE CITY , OCT. 30, 2025 /PRNEWSWIRE/ --CO-DIAGNOSTICS, INC. (NASDAQ: CODX) (THE "COMPANY" OR "CO-DX"), A MOLECULAR DIAGNOSTICS COMPANY WITH A UNIQUE, PATENTED PLATFORM FOR THE DEVELOPMENT OF MOLECULAR DIAGNOSTIC TESTS, ANNOUNCED TODAY THAT IT WILL HOST A VIRTUAL FIRESIDE CHAT ON WEDNESDAY, NOVEMBER 5, 2025 AT 11:00 AM ET. JOIN DWIGHT EGAN, CEO OF CO-DX, FOR AN UPDATE ON THE COMPANY'S GROWTH INITIATIVES, INCLUDING ITS RECENTLY ANNOUNCED DEFINITIVE AGREEMENT WITH ARABIAN EAGLE IN THE KINGDOM OF SAUDI ARABIA TO FORM COMIRA DIAGNOSTICS AND TO ADVANCE THE REGIONAL DEPLOYMENT OF THE CO-DX PCR PLATFORM* ACROSS THE MIDDLE EAST.

CO-DIAGNOSTICS TO HOST FIRESIDE CHAT ON NOVEMBER 5TH WITH CEO, DWIGHT EGAN, TO DISCUSS RECENTLY ANNOUNCED DEFINITIVE AGREEMENT IN SAUDI ARABIA

SALT LAKE CITY , OCT. 29, 2025 /PRNEWSWIRE/ -- CO-DIAGNOSTICS, INC.(NASDAQ: CODX)(THE "COMPANY" OR "CO-DX"), A MOLECULAR DIAGNOSTICS COMPANY WITH A UNIQUE, PATENTED PLATFORM FOR THE DEVELOPMENT OF MOLECULAR DIAGNOSTIC TESTS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED OFFERING OF 12,727,272 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN-LIEU THEREOF) AT AN OFFERING PRICE OF $0.55 PER SHARE (THE "OFFERING"). THE GROSS PROCEEDS TO THE COMPANY FROM THE OFFERING WERE APPROXIMATELY $7.0 MILLION BEFORE DEDUCTING THE PLACEMENT AGENT'S FEES AND OTHER OFFERING EXPENSES.

CO-DIAGNOSTICS, INC. ANNOUNCES CLOSING OF $7.0 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES

SALT LAKE CITY , OCT. 28, 2025 /PRNEWSWIRE/ -- CO-DIAGNOSTICS, INC.(NASDAQ: CODX)(THE "COMPANY" OR "CO-DX"), A MOLECULAR DIAGNOSTICS COMPANY WITH A UNIQUE, PATENTED PLATFORM FOR THE DEVELOPMENT OF MOLECULAR DIAGNOSTIC TESTS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH SEVERAL INSTITUTIONAL INVESTORS FOR THE PURCHASE AND SALE OF 12,727,272 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN-LIEU THEREOF) AT AN OFFERING PRICE OF $0.55 PER SHARE, IN A REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES (THE "OFFERING"). THE GROSS PROCEEDS TO THE COMPANY FROM THE OFFERING ARE ESTIMATED TO BE APPROXIMATELY $7.0 MILLION BEFORE DEDUCTING THE PLACEMENT AGENT'S FEES AND OTHER ESTIMATED OFFERING EXPENSES.

CO-DIAGNOSTICS, INC. ANNOUNCES PRICING OF $7.0 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES

CONFERENCE ATTENDANCE FOLLOWS RECENT MOU ANNOUNCEMENT FOR A JOINT VENTURE WITH A REGIONAL MANUFACTURING AND DISTRIBUTION COMPANY IN THE KINGDOM OF SAUDI ARABIA SALT LAKE CITY , OCT. 22, 2025 /PRNEWSWIRE/ --CO-DIAGNOSTICS, INC. (NASDAQ: CODX) (THE "COMPANY" OR "CO-DX"), A MOLECULAR DIAGNOSTICS COMPANY WITH A UNIQUE, PATENTED PLATFORM FOR THE DEVELOPMENT OF MOLECULAR DIAGNOSTIC TESTS, ANNOUNCED TODAY THAT MEMBERS OF THE COMPANY'S EXECUTIVE LEADERSHIP TEAM WILL BE IN ATTENDANCE AND HOST A BOOTH AT GLOBAL HEALTH EXHIBITION 2025 AT THE RIYADH EXHIBITION & CONVENTION CENTER ON OCTOBER 27-30 IN RIYADH, KINGDOM OF SAUDI ARABIA (KSA). REPRESENTING THE COMPANY WILL BE CO-DX CHAIRMAN OF THE BOARD AND CEO DWIGHT EGAN, AS WELL AS THE COMPANY'S PRESIDENT, RICHARD ABBOTT, CHIEF COMMERCIALIZATION AND STRATEGY OFFICER SETH EGAN, OTHER DEPARTMENT HEADS AND CRITICAL STAFF, AND EUGENE DURENARD FROM THE CO-DIAGNOSTICS BOARD OF DIRECTORS AND CHAIRMAN OF THE AUDIT COMMITTEE.

Co-Diagnostics, Inc.

CODX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Co-Diagnostics, Inc.

CODX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CODX